Lupin Manufacturing Solutions, PolyPeptide form strategic peptide alliance

On December 12, 2025, Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, disclosed a strategic alliance with PolyPeptide Group AG, a specialized CDMO for peptide-based active pharmaceutical ingredients. This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the expanding global peptides market, including next-generation peptide therapeutics for metabolics.

The alliance will focus on expanding sourcing options to meet rising global demand for peptide APIs, integrating procurement and supply planning, and ensuring quality and reliability in global service delivery. This partnership positions LMS as a leading CDMO supplier of peptide materials for innovator and generic markets, while strengthening PolyPeptide's standing as a trusted CDMO partner.

PolyPeptide, established in 1952, operates a global network of six GMP-certified facilities across Europe, the U.S., and India, serving the pharmaceutical and biotech sectors from pre-clinical to commercial stages. LMS, a subsidiary of Lupin Limited, offers standalone and integrated solutions across various drug substances and advanced modalities, supporting biopharma innovators from early development to commercial scale.